Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST study.
Gerdes S, Hoffmann M, Asadullah K, Korge B, Mortazawi D, Krüger N, Personke Y, Tabori S, Gomez M, Wegner S, Kreimendahl F, Taut F, Sticherling M. Gerdes S, et al. Among authors: korge b. J Eur Acad Dermatol Venereol. 2023 Jul 18. doi: 10.1111/jdv.19296. Online ahead of print. J Eur Acad Dermatol Venereol. 2023. PMID: 37462295
Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
Korge B, Vanhooteghem O, Lynde CW, Machovcova A, Perrussel M, Lazaridou E, Marasca C, Sarro DV, Pousa ID, Fierens F, Williams P, Shimizu S, Heidbrede T, Warren RB. Korge B, et al. Dermatol Ther (Heidelb). 2024 Aug;14(8):2077-2092. doi: 10.1007/s13555-024-01210-3. Epub 2024 Jun 27. Dermatol Ther (Heidelb). 2024. PMID: 38937404 Free PMC article.
Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
Korge B, Vanhooteghem O, Lynde CW, Machovcova A, Perrussel M, Lazaridou E, Marasca C, Sarro DV, Pousa ID, Fierens F, Williams P, Shimizu S, Heidbrede T, Warren RB. Korge B, et al. Dermatol Ther (Heidelb). 2024 Oct;14(10):2923-2926. doi: 10.1007/s13555-024-01271-4. Dermatol Ther (Heidelb). 2024. PMID: 39340697 Free PMC article. No abstract available.
Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
Gerdes S, Asadullah K, Hoffmann M, Korge B, Mortazawi D, Wegner S, Personke Y, Gomez M, Sticherling M. Gerdes S, et al. Among authors: korge b. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1568-1577. doi: 10.1111/jdv.18218. Epub 2022 May 25. J Eur Acad Dermatol Venereol. 2022. PMID: 35569014
Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO.
Reich K, Korge B, Magnolo N, Manasterski M, Schwichtenberg U, Staubach-Renz P, Kaiser S, Roemmler-Zehrer J, Gómez NN, Lorenz-Baath K. Reich K, et al. Among authors: korge b. Dermatol Ther (Heidelb). 2022 Jan;12(1):203-221. doi: 10.1007/s13555-021-00658-x. Epub 2021 Dec 15. Dermatol Ther (Heidelb). 2022. PMID: 34913153 Free PMC article.
Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
Gerdes S, Bräu B, Hoffmann M, Korge B, Mortazawi D, Wiemers F, Wegner S, Personke Y, Gomez M, Sticherling M. Gerdes S, et al. Among authors: korge b. J Dermatol. 2021 Dec;48(12):1854-1862. doi: 10.1111/1346-8138.16128. Epub 2021 Sep 12. J Dermatol. 2021. PMID: 34510527
54 results